Jessica Lin: Preclinical development and proof-of-concept clinical activity of NVL-655

Jessica Lin shared a post on LinkedIn:

“We are pleased to share this article out today in Cancer Discovery on the preclinical development and proof-of-concept clinical activity of NVL-655 4th-generation, ALK-selective TKI CNS-penetrant.
Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound mutations.

Fills an important unmet need for pts with ALK+ lung cancer and other solid tumors.

Tune in for updated prelim efficacy & safety data from the global ongoing phase I/II study (ALKOVE-1) of NVL-655 to be presented TOMORROW at ESMO2024!”

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations 

Authors: Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola W. Zhu, Enriqueta Felip, Byoung Chul Cho, Luc Friboulet, Aaron N. Hata, Henry E. Pelish and Alexander Drilon.

Source: Jessica Lin/LinkedIn

Jessica J. Lin, MD, is an attending physician at the Center for Thoracic Cancers and the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. Dr. Lin’s research focuses on driver oncogene alterations in non-small cell lung cancer and the development of resistance to targeted therapies. She leads clinical trials exploring new targeted therapies and immunotherapies for lung cancer.